Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 406-408

  Guo, Shanxian ^a   Liang, Yonggang ^a   Zhou, Qinghua ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN; CARBOPLATIN;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LUNG SMALL CELL CANCER; META ANALYSIS (TOPIC); NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER RISK; CANCER STAGING; SENSITIVITY ANALYSIS;

EID: 79551560232     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182061d8c     Document Type: Letter

References (3)

1. Jiang J, Liang X, Zhou X, et al. A metaanalysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-873.
2. Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010;21:1810-1816.
3. Bigby M. Odds ratios and relative risks. Arch Dermatol 2000;136:770-771.